2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
1
Melanoma
1
Colorectal Cancer Metastatic
1
Carcinoma, Merkel Cell
1
Interventions
Bevacizumab
19
Capecitabine
15
Oxaliplatin
11
Irinotecan
11
Cetuximab
11
Fluorouracil
10
Leucovorin
8
aflibercept
7
Panitumumab
6
trifluridine tipiracil drug combination
4
Nivolumab
4
sintilimab
3
regorafenib
3
Ipilimumab
3
Vemurafenib
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
HMPL-013
2
Folfox protocol
2
Drug Therapy
2
tremelimumab
1
spartalizumab
1
raltitrexed
1
pembrolizumab
1
monoclonal antibody YYB-101
1
masitinib
1
irinotecan sucrosofate
1
glucopyranosyl lipid-A
1
folfirinox
1
durvalumab
1
camrelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Cancer Metastatic
×
glucopyranosyl lipid-A
×
Clear all
NCT03982121
2020-02-17
ISILI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn